AI Breakthrough Predicts Bowel Cancer Drug Response on NHS
Scientists have unveiled a groundbreaking artificial intelligence model named PhenMap, designed to identify which patients with advanced bowel cancer are most likely to respond to the targeted NHS drug bevacizumab. This development promises to transform cancer care by enabling more precise and effective treatment strategies.
Targeting Ineffective Treatment and Side Effects
Bevacizumab, approved for use in advanced bowel cancer within the NHS, is effective for only a small subset of patients and carries significant risks of serious side effects. The new AI tool aims to address this critical issue by predicting drug response, thereby preventing patients from undergoing futile treatments and experiencing unnecessary adverse reactions.
How PhenMap Works
Developed through a collaborative effort by researchers at the Institute of Cancer Research in London and RCSI University of Medicine and Health Sciences in Dublin, PhenMap integrates complex genetic and clinical data. By analysing this information, the AI model can stratify patients based on their likelihood of benefiting from bevacizumab, offering a more personalised approach to cancer therapy.
Potential to Revolutionise Cancer Research
This AI-driven approach holds the potential to revolutionise cancer research by enabling more accurate patient stratification. Beyond bowel cancer, PhenMap could be adapted for use with other targeted therapies, paving the way for broader applications in oncology and improving outcomes across various cancer types.
The tool's development underscores a growing trend towards precision medicine, where treatments are tailored to individual patient profiles. As cancer remains a leading cause of death globally, innovations like PhenMap represent a significant step forward in enhancing patient care and optimising healthcare resources.
